Sanofi-Aventis signs cancer deal with Micromet
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis is to pay Micromet €8 million upfront as part of a global licensing agreement for the development of a BiTE antibody against an antigen present in carcinoma cells.